ORCL
Q3 2026 EPS Estimate
$1.72
Sep 8, 2026 · Reports after close
Revenue Estimate
$19.13B
FY2027E EPS$8.06
FY2028E EPS$10.92

Analyst Sentiment

Wall St. Consensus
Buy
33 analysts·High coverage
72
Score
29 Buy (88%)4 Hold (12%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
2988%
Hold
412%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$95.00
-39.1%
Consensus
$241.00
+54.5%
Bull
$325.00
+108.3%
12-Month Target Range33 analysts
$95.00$241.00$325.00
Current $155.99Consensus
Current Price
$155.99
Upside to Consensus
$85.01

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+33.23%
EPS+7.62%
FY2028
Rev+45.51%
EPS+35.57%
FY2029
Rev+38.14%
EPS+41.39%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2027EFY2028EFY2029EFY2030EFY2031E
Revenue Avg$89.61B$130.40B$180.13B$218.50B$257.13B
Low$88.62B$119.29B$146.59B$189.93B$223.51B
High$90.39B$138.65B$200.49B$231.56B$272.50B
EBITDA Avg$35.69B$51.94B$71.75B$87.03B$102.42B
Low$35.30B$47.51B$58.39B$75.65B$89.02B
High$36.00B$55.22B$79.85B$92.23B$108.54B
EBIT Avg$26.06B$37.93B$52.39B$63.55B$74.79B
Low$25.77B$34.70B$42.64B$55.24B$65.01B
High$26.29B$40.33B$58.31B$67.35B$79.26B
Net Income Avg$23.30B$32.72B$47.69B$57.63B$69.81B
Low$22.82B$24.67B$30.78B$47.83B$57.95B
High$23.78B$35.69B$53.27B$62.11B$75.24B
EPS Avg$8.06$10.92$15.45$19.77$23.95
Low$7.83$8.46$10.56$16.41$19.88
High$8.16$12.24$18.27$21.31$25.81
Analysts (Rev / EPS)32 / 2630 / 2422 / 1111 / 719 / 9
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$19.13B$21.16B$23.22B$26.29B$27.17B$30.56B$34.35B$39.42B
Low$19.10B$20.68B$22.64B$25.63B$26.49B$29.80B$33.49B$38.44B
High$19.20B$21.35B$23.54B$26.65B$27.55B$30.98B$34.82B$39.97B
EBITDA Avg$7.62B$8.43B$9.25B$10.47B$10.82B$12.17B$13.68B$15.70B
Low$7.61B$8.24B$9.02B$10.21B$10.55B$11.87B$13.34B$15.31B
High$7.65B$8.50B$9.38B$10.62B$10.97B$12.34B$13.87B$15.92B
EBIT Avg$5.56B$6.15B$6.75B$7.65B$7.90B$8.89B$9.99B$11.47B
Low$5.55B$6.01B$6.58B$7.46B$7.71B$8.67B$9.74B$11.18B
High$5.58B$6.21B$6.85B$7.75B$8.01B$9.01B$10.13B$11.62B
Net Income Avg$5.05B$5.51B$6.00B$6.91B$6.53B$7.32B$8.38B$9.83B
Low$4.52B$4.95B$5.81B$6.69B$6.32B$7.08B$8.11B$9.51B
High$5.17B$5.89B$6.11B$7.04B$6.65B$7.45B$8.53B$10.01B
EPS Avg$1.73$1.89$2.06$2.37$2.24$2.51$2.87$3.37
Low$1.55$1.70$1.99$2.29$2.17$2.43$2.78$3.26
High$1.77$2.02$2.10$2.41$2.28$2.56$2.93$3.43
Analysts (Rev / EPS)20 / 2220 / 2110 / 1810 / 910 / 1210 / 179 / 109 / 11

Earnings Surprises

Recent Analyst Actions

Aug 12, 2026Bernstein
Quantinuum Inc (QNT) PT Raised to $95 at Bernstein SocGen Group
Target:$95.00
-36.2%from $148.91
Aug 6, 2026UBS
Oracle price target lowered to $245 from $285 at UBS
Target:$245.00
+69.7%from $144.36
Jul 20, 2026CLSA
Oracle initiated with a Hold at CLSA
Target:$145.00
+14.6%from $126.48
Jun 11, 2026D.A. Davidson
Oracle price target raised to $225 from $200 at DA Davidson
Target:$225.00
+24.8%from $180.22
Jun 11, 2026Wedbush
Oracle price target lowered to $240 from $275 at Wedbush
Target:$240.00
+19.2%from $201.26
Jun 11, 2026BMO Capital
Oracle price target raised to $220 from $200 at BMO Capital
Target:$220.00
+9.3%from $201.26
Jun 11, 2026Bernstein
Oracle price target raised to $325 from $319 at Bernstein
Target:$325.00
+61.5%from $201.26
Jun 11, 2026Piper Sandler
Oracle price target raised to $225 from $210 at Piper Sandler
Target:$225.00
+11.8%from $201.26
Jun 11, 2026Scotiabank
Oracle (ORCL) PT Lowered to $241 at Scotiabank
Target:$241.00
+19.7%from $201.26
Jun 11, 2026Wolfe Research
Oracle (ORCL) PT Raised to $225 at Wolfe Research, 'We remain positive'
Target:$225.00
+11.8%from $201.26
Jun 11, 2026Barclays
Oracle (ORCL) PT Raised to $250 at Barclays
Target:$250.00
+24.2%from $201.26
Jun 11, 2026MoffettNathanson
Oracle (ORCL) PT Raised to $325 at Bernstein SocGen Group
Target:$325.00
+61.5%from $201.26
Jun 8, 2026Oppenheimer
Oracle (ORCL) PT Raised to $275 at Oppenheimer
Target:$275.00
+28.9%from $213.41
Jun 8, 2026Evercore ISI
Oracle (ORCL) PT Raised to $245 at Evercore ISI
Target:$245.00
+14.8%from $213.41
Jun 5, 2026Cantor Fitzgerald
Oracle price target raised to $284 from $229 at Cantor Fitzgerald
Target:$284.00
+29.0%from $220.15
Jun 4, 2026RBC Capital
Oracle price target raised to $190 from $160 at RBC Capital
Target:$190.00
-19.6%from $236.34
Jun 3, 2026Mizuho Securities
Mizuho Reiterates Outperform Rating on Oracle (ORCL)
Target:$320.00
+30.9%from $244.54
Jun 2, 2026UBS
Oracle (ORCL) PT Raised to $285 at UBS Ahead of Q4 Results
Target:$285.00
+19.0%from $239.41
Jun 2, 2026Scotiabank
Oracle (ORCL) PT Raised to $290 at Scotiabank
Target:$290.00
+16.9%from $248.07
May 13, 2026Wedbush
Oracle price target raised to $275 from $225 at Wedbush
Target:$275.00
+46.5%from $187.74
May 12, 2026Oppenheimer
Oracle price target raised to $235 from $210 at Oppenheimer
Target:$235.00
+21.2%from $193.83
May 7, 2026Arete Research
Oracle upgraded to Buy from Neutral at Arete
Target:$255.00
+31.5%from $193.99
Apr 24, 2026Wedbush
Oracle initiated with an Outperform at Wedbush
Target:$225.00
+27.6%from $176.28
Apr 23, 2026Morgan Stanley
Oracle price target lowered to $207 from $213 at Morgan Stanley
Target:$207.00
+17.8%from $175.66
Mar 11, 2026Deutsche Bank
Deutsche Bank Reiterates Buy Rating on Oracle (ORCL) following Q3 results: "plenty to like in this print"
Target:$300.00
+84.8%from $162.32
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.